Kimberly Lynn Blackwell, MD

Professor of Medicine
Assistant Professor in Radiation Oncology
Member of the Duke Cancer Institute
Campus mail Duke Box 3893, Durham, NC 27710
Phone (919) 668-1748
Email address

Breast cancer angiogenesis
Breast cancer in younger women
Hormonal therapy
Neoadjurant therapy for breast cancer

Current Clinical Investigations

Principal Investigator, A Phase I-II Study of Neoadjuvant Evacet/Paclitaxel/Hyperthermia in Locally Advanced Breast Cancer Patients.

Investigator, Development of Screening Markers for Breast Cancer using Circulating Immune Complexes: Collaborative Study with Diagen Medical Technologies.

Principal Investigator, Use of Plasma D-Dimer as a Predictive Marker in Colorectal Carcinoma: Correlative Science Study with Genentech, Inc.

Principal Investigator, A randomized, Phase II study of gabapentin or glutamine to prevent the peripheral neuropathy/myalgia associated with weekly taxol administration in metastatic breast and lung cancer.

Investigator, A Phase 2, Randomized, Double-Masked, Multicenter Study of Two Dose Levels of ERA-923 for the treatment of Metastatic Breast Cancer in Postmenopausal Women who have failed Tamoxifen therapy. Genetics Institute.

Investigator, A Phase I Study of Combined Doxil/Hyperthermia in Stage IV Breast Cancer.

Education and Training

  • Fellow In Hematology Oncology, Medicine, Duke University, 1997 - 2000
  • Medical Resident, Medicine, Duke University, 1994 - 1997
  • M.D., Mayo School of Health Sciences, 1994


Blackwell, K, Donskih, R, Jones, CM, Nixon, A, Vidal, MJ, Nakov, R, Singh, P, Schaffar, G, Gascon, P, and Harbeck, N. "A Comparison of Proposed Biosimilar LA-EP2006 and Reference Pegfilgrastim for the Prevention of Neutropenia in Patients With Early-Stage Breast Cancer Receiving Myelosuppressive Adjuvant or Neoadjuvant Chemotherapy: Pegfilgrastim Randomized Oncology (Supportive Care) Trial to Evaluate Comparative Treatment (PROTECT-2), a Phase III, Randomized, Double-Blind Trial." The Oncologist 21, no. 7 (July 1, 2016): 789-794.

Full Text

Farber, SH, Tsvankin, V, Narloch, JL, Kim, GJ, Salama, AK, Vlahovic, G, Blackwell, KL, Kirkpatrick, JP, and Fecci, PE. "Embracing rejection: Immunologic trends in brain metastasis. (Published online)" Oncoimmunology 5, no. 7 (July 2016): e1172153-. (Review)

Full Text

Harbeck, N, Lipatov, O, Frolova, M, Udovitsa, D, Topuzov, E, Ganea-Motan, DE, Nakov, R, Singh, P, Rudy, A, and Blackwell, K. "Randomized, double-blind study comparing proposed biosimilar LA-EP2006 with reference pegfilgrastim in breast cancer." Future Oncology 12, no. 11 (June 2016): 1359-1367.

Full Text

Freedman, RA, Gelman, RS, Wefel, JS, Melisko, ME, Hess, KR, Connolly, RM, Van Poznak, CH, Niravath, PA, Puhalla, SL, Ibrahim, N, Blackwell, KL, Moy, B, Herold, C, Liu, MC, Lowe, A, Agar, NY, Ryabin, N, Farooq, S, Lawler, E, Rimawi, MF, Krop, IE, Wolff, AC, Winer, EP, and Lin, NU. "Translational Breast Cancer Research Consortium (TBCRC) 022: A Phase II Trial of Neratinib for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases." Journal of clinical oncology : official journal of the American Society of Clinical Oncology 34, no. 9 (March 2016): 945-952.


Harnden, KK, and Blackwell, KL. "Increased Fiber Intake Decreases Premenopausal Breast Cancer Risk." Pediatrics 137, no. 3 (March 2016): e20154376-.


Blackwell, K, Burris, H, Gomez, P, Lynn Henry, N, Isakoff, S, Campana, F, Gao, L, Jiang, J, Macé, S, and Tolaney, SM. "Phase I/II dose-escalation study of PI3K inhibitors pilaralisib or voxtalisib in combination with letrozole in patients with hormone-receptor-positive and HER2-negative metastatic breast cancer refractory to a non-steroidal aromatase inhibitor." Breast Cancer Research and Treatment 154, no. 2 (November 2015): 287-297.

Full Text

Kimmick, G, Edmond, SN, Bosworth, HB, Peppercorn, J, Marcom, PK, Blackwell, K, Keefe, FJ, and Shelby, RA. "Medication taking behaviors among breast cancer patients on adjuvant endocrine therapy." Breast (Edinburgh, Scotland) 24, no. 5 (October 2015): 630-636.


Blackwell, K, Semiglazov, V, Krasnozhon, D, Davidenko, I, Nelyubina, L, Nakov, R, Stiegler, G, Singh, P, Schwebig, A, Kramer, S, and Harbeck, N. "Comparison of EP2006, a filgrastim biosimilar, to the reference: a phase III, randomized, double-blind clinical study in the prevention of severe neutropenia in patients with breast cancer receiving myelosuppressive chemotherapy." Annals of Oncology 26, no. 9 (September 2015): 1948-1953.

Full Text

Siamakpour-Reihani, S, Owzar, K, Jiang, C, Scarbrough, PM, Craciunescu, OI, Horton, JK, Dressman, HK, Blackwell, KL, and Dewhirst, MW. "Genomic profiling in locally advanced and inflammatory breast cancer and its link to DCE-MRI and overall survival." International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group 31, no. 4 (June 2015): 386-395.


Harnden, K, and Blackwell, K. "Routine use of zoledronic acid in early-stage breast cancer." JNCCN Journal of the National Comprehensive Cancer Network 13, no. 4 (January 1, 2015): 480-486. (Review)